Orphan status for pancreatic cancer treatment

The European Commission has just granted Orphan drug status to the BL-8040 (Motixafortide) pancreatic cancer treatment from Israel’s BioLineRX (see here). BioLineRX can now receive benefits including EU funding, less regulation, and market exclusivity.


This entry was posted in Israel's Medical Achievements. Bookmark the permalink.

Leave a Reply

Your email address will not be published. Required fields are marked *